NEW YORK, February 20, 2013 /PRNewswire/ --
Today, National Traders Association announced new research reports highlighting General Mills, Inc. (NYSE: GIS), GlaxoSmithKline plc. (NYSE: GSK), Pfizer Inc. (NYSE: PFE), the Coca-Cola Company (NYSE: KO) and Dr. Pepper Snapple Group, Inc. (NYSE: DPS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
General Mills, Inc. Research Report
General Mills hit its 52-week high last week at $41.92, with The Street rating the company as a "buy," citing revenue growth, good cash flow from operations, net income growth, among others, which outweigh its "generally high" debt management risk. General Mills started reducing its workforce and production costs of other products amid acquisitions and growing wholesale orders to avoid increasing end prices and keep up with expected revenues. However, analysts at Goldman Sachs are not optimistic with the company's new cereal lineup this year, and won't make up the subpar numbers elsewhere. In addition, its Yoplait yoghurt is underperforming despite the popularity of Greek yogurt. The Full Research Report on General Mills, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.nationaltradersassociation.org/r/entire_report/ac13_GIS]
GlaxoSmithKline plc. Research Report
A cure for Alzheimer's is the main focus of GlaxoSmithKline. A research team in University Laval in Canada has discerned a way to encourage the brains defense system to naturally combat Alzheimer's. The breakthrough in this is that the cure itself is already available through GlaxoSmithKline's portfolio as it is an active ingredient in the healthcare company's records for years. Research has tested that after injecting mice that show Alzheimer's symptoms, within months' time the mice have shown astonishing improvement in their ability in terms of comprehension and learning. Discoveries like this will propagate the company's record in breakthrough medicine, and its contribution to curing the 6th probable cause of death in the United States. The Full Research Report on GlaxoSmithKline plc. - Including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.nationaltradersassociation.org/r/entire_report/7072_GSK]
Pfizer Inc. Research Report
Pfizer on the other hand recently launched its subsidiary Zoetis (NYSE: ZTS) to the NYSE and has been making the headlines for having the biggest initial public offering since Facebook at $26. Having a 60-year animal healthcare history with Pfizer, it is but natural that its executive team came from its mother company. Five out of nine of its current board members currently work at Pfizer. The response has been more than impressive as originally its proposed price were in the $22 to $25 dollars, but the amount of interest from investors had led it to push its IPO price to $26 and earning an initial IPO of US$2.24 billion. Zoetis will be trading independently from Pfizer, but the company itself will be owned by the majority of the pharmaceutical giant. Zoetis' debut was the biggest since Facebook's IPO in the mid-2011, earning US$16.02 billion. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.nationaltradersassociation.org/r/entire_report/bd2d_PFE]
The Coca-Cola Company Research Report
With these developments, top soda makers have begun looking for ways in order to remain strong in the US and other developed countries. One of the Coca-Cola Company's strategies was to launch an anti-obesity ad campaign, but it was duly met with much criticism. Another strategy that Coca-Cola is using is to expand its portfolio of non-carbonated drinks. At present, Coca-Cola has a leading position in the juices or still beverages category with Minute Maid, Simply and PowerAde. To add to this line of products, the company has purchased stakes in Fair Oaks Farms Brands, LLC, a company that produces high-protein milk shakes, creating a new portfolio of healthy beverages with high growth potential. . The Full Research Report on The Coca-Cola Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.nationaltradersassociation.org/r/entire_report/83ff_KO]
Dr. Pepper Snapple Group, Inc. Research Report
Dr. Pepper Snapple Group Inc. responded with a new line of 10 calorie versions of 7-Up, Sunkist and three other sodas after launching a 10-calorie version of Dr. Pepper in 2012. It is the only company that continues to thrive in the US, with 70% of its sales coming from soda, and about 90% of its revenue from the US. Dr. Pepper hopes to redefine the image of diet soda and win back soda drinkers who wish to reduce their calorie intakes. Diet soda already accounts for 20 percent of Dr. Pepper's soda sales and Larry Young, CEO of Plano, the Texas-based Dr. Snapple Group, sees that the figure could reach between 40 to 50 percent in the next few years. The Full Research Report on Dr. Pepper Snapple Group, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.nationaltradersassociation.org/r/entire_report/c007_DPS]
Consider National Traders Association
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.
Contact: Demi Lapierre Email: press@NationalTradersAssociation.org Main: +1-(702)-212-4493
SOURCE National Traders Association